NASDAQ:HURA TuHURA Biosciences (HURA) Stock Price, News & Analysis $2.51 0.00 (0.00%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.49 -0.02 (-0.80%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TuHURA Biosciences Stock (NASDAQ:HURA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TuHURA Biosciences alerts:Sign Up Key Stats Today's Range$2.40▼$2.6550-Day Range$1.41▼$3.1552-Week Range$0.41▼$4.05Volume340,301 shsAverage Volume865,704 shsMarket Capitalization$159.84 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company Overview TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies. At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states. This platform enables the identification of previously unrecognized biological pathways and target proteins, supporting both small‐molecule and biologic drug discovery. The technology is designed to accelerate early‐stage research by revealing disease drivers that traditional genomics and transcriptomics methods may overlook. TuHURA is advancing a pipeline of programs in areas such as immunology, neurodegeneration and female health. The company has entered research collaborations with pharmaceutical and academic partners to validate targets and co‐develop lead candidates. These partnerships are helping TuHURA expand its reach into therapeutic areas of high unmet medical need while leveraging external expertise and resources. Founded as a spin‐out from the University of California, Davis technology transfer office, TuHURA Biosciences is headquartered in California and serves a global research community. The company completed its initial public offering on the Nasdaq Capital Market under the ticker HURA in 2022, positioning itself for continued growth and innovation in proteomics‐driven drug discovery.AI Generated. May Contain Errors. Read More TuHURA Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreHURA MarketRank™: TuHURA Biosciences scored higher than 54% of companies evaluated by MarketBeat, and ranked 490th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingTuHURA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTuHURA Biosciences has a consensus price target of $9.00, representing about 258.6% upside from its current price of $2.51.Amount of Analyst CoverageTuHURA Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about TuHURA Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TuHURA Biosciences are expected to grow in the coming year, from ($0.45) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TuHURA Biosciences is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TuHURA Biosciences is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTuHURA Biosciences has a P/B Ratio of 7.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TuHURA Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.00% of the float of TuHURA Biosciences has been sold short.Short Interest Ratio / Days to CoverTuHURA Biosciences has a short interest ratio ("days to cover") of 7.77.Change versus previous monthShort interest in TuHURA Biosciences has recently decreased by 0.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTuHURA Biosciences does not currently pay a dividend.Dividend GrowthTuHURA Biosciences does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.65 News SentimentTuHURA Biosciences has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for TuHURA Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for HURA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added TuHURA Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TuHURA Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders0.20% of the stock of TuHURA Biosciences is held by insiders.Percentage Held by Institutions0.62% of the stock of TuHURA Biosciences is held by institutions.Read more about TuHURA Biosciences' insider trading history. Receive HURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HURA Stock News HeadlinesTuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceMay 12 at 7:30 AM | prnewswire.comTuHURA Biosciences (HURA) Projected to Post Earnings on FridayMay 8, 2026 | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 15 at 1:00 AM | Banyan Hill Publishing (Ad)Citizens Initiates Coverage of TuHURA Biosciences (HURA) with Market Outperform RecommendationApril 28, 2026 | msn.comTuHURA Biosciences Secures $50 Million Credit FacilityApril 22, 2026 | tipranks.comTuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028April 22, 2026 | prnewswire.comIs TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?April 20, 2026 | finance.yahoo.comTuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical OperationsApril 7, 2026 | prnewswire.comSee More Headlines HURA Stock Analysis - Frequently Asked Questions How have HURA shares performed this year? TuHURA Biosciences' stock was trading at $0.7567 at the beginning of the year. Since then, HURA stock has increased by 231.7% and is now trading at $2.51. How were TuHURA Biosciences' earnings last quarter? TuHURA Biosciences, Inc. (NASDAQ:HURA) issued its quarterly earnings data on Tuesday, March, 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. Who are TuHURA Biosciences' major shareholders? Top institutional investors of TuHURA Biosciences include Apollon Wealth Management LLC (0.25%), Cetera Investment Advisers (0.22%), WealthShield Partners LLC (0.14%) and Greenline Wealth Management LLC (0.06%). How do I buy shares of TuHURA Biosciences? Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/31/2026Today5/15/2026Next Earnings (Estimated)5/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 HURA's financial health is in the Green zone, according to TradeSmith. HURA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HURA Previous SymbolNASDAQ:HURA CIK1498382 WebN/A Phone(813) 875-6600Fax604-608-5685EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for TuHURA Biosciences$9.00 High Price Target$10.00 Low Price Target$8.00 Potential Upside/Downside+258.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.05 million Net MarginsN/A Pretax MarginN/A Return on Equity-182.40% Return on Assets-117.49% Debt Debt-to-Equity RatioN/A Current Ratio0.78 Quick Ratio0.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book7.38Miscellaneous Outstanding Shares63,680,000Free Float63,556,000Market Cap$159.84 million OptionableN/A Beta-0.01 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:HURA) was last updated on 5/15/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
